- Inicio
- Publicaciones
- Anti-thymocyte globulin (ATG)- or alemtuzumab-based graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) for patients 40 years and older with acute lymphoblastic leukemia in first complete remission: a study from the EBMT Acute Leukemia Working Party
Anti-thymocyte globulin (ATG)- or alemtuzumab-based graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) for patients 40 years and older with acute lymphoblastic leukemia in first complete remission: a study from the EBMT Acute Leukemia Working Party
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Bug G.
- Labopin M.
- Byrne J.L.
- Mielke S.
- Orchard K.
- Paneesha S.
- Potter V.
- Blaise D.
- Besley C.
- Snowden J.A.
- Yakoub-Agha I.
- Clark A.
- Crawley C.
- Spyridonidis A.
- Brissot E.
- Giebel S.
- Ciceri F.
- Mohty M.
Grupos
Abstract
For patients with high-risk acute lymphoblastic leukemia (ALL), allogeneic hematopoietic cell transplantation (HCT) remains standard of care. In the setting of an HLA-matched unrelated donor HCT, in vivo T-cell depletion (TCD) for prophylaxis of graft versus host disease (GVHD) relies on anti-thymocyte globulin (ATG) in Europe and alemtuzumab in the UK. In a retrospective study from the EBMT registry, we pair-matched 90 ALL patients aged =40 years transplanted in CR1 according to age (median 56 years) and ALL subtype (37.8% Ph-negative B-ALL, 46.7% Ph-positive B-ALL, 15.6% T-ALL). Reduced-intensity conditioning included fludarabine/melphalan (94.4%) in the alemtuzumab and fludarabine/busulfan (36.7%), fludarabine/total body irradiation (21.1%), fludarabine/melphalan (14.4%) and thiotepa/busulfan/fludarabine (13.3%) in the ATG group. Two-year leukemia-free and overall survival were similar between groups (Alemtuzumab: 56.4% vs ATG: 50.7%, HR 0.82, p = 0.34, and 62.7% vs 62.9%, HR 0.91, p = 0.67), as were cumulative incidence of relapse (23.7% vs 23.9%, HR 0.89, p = 0.69) and non-relapse mortality (19.9% vs 25.4%, HR 0.75, p = 0.32), resulting in similar GVHD- and relapse-free survival (GRFS) of 48.9% vs 42.1%, HR 0.8, p = 0.24. With GVHD and infections as main reasons for death in both groups, we conclude that both IS strategies are both safe for RIC HCT of these ALL patients. © The Author(s) 2026.
Datos de la publicación
- ISSN/ISSNe:
- 0268-3369, 1476-5365
- Tipo:
- Article
- Páginas:
- 462-468
- PubMed:
- 41792300
- Enlace a otro recurso:
- www.scopus.com
- Factor de Impacto:
- 0,998 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
BONE MARROW TRANSPLANTATION SPRINGERNATURE
Citas Recibidas en Web of Science: 1
Citas Recibidas en Scopus: 1
Documentos
- No hay documentos
Filiaciones
Keywords
- Adult; Aged; Alemtuzumab; Antilymphocyte Serum; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; alemtuzumab; lymphocyte antibody; adult; aged; allotransplantation; B cell acute lymphoblastic leukemia; clinical trial; female; graft versus host reaction; hematopoietic stem cell transplantation; human; male; middle aged; mortality; multicenter study; prevention and control; procedures; remission; retrospective study; therapy; transplantation conditioning
Cita
Bug G,Labopin M,Byrne JL,Mielke S,Orchard K,Paneesha S,Potter V,Blaise D,Besley C,Snowden JA,Yakoub I,Clark A,Crawley C,Spyridonidis A,SANZ J,Brissot E,Giebel S,Ciceri F,Mohty M. Anti-thymocyte globulin (ATG)- or alemtuzumab-based graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) for patients 40 years and older with acute lymphoblastic leukemia in first complete remission: a study from the EBMT Acute Leukemia Working Party. Bone Marrow Transplant. 2026. 61. (4):p. 462-468. IF:5,100. (1).
Portal de investigación